Last reviewed · How we verify
L-Tyrosine
L-Tyrosine is a Amino acid supplement Small molecule drug developed by Hadassah Medical Organization. It is currently FDA-approved for Cognitive performance enhancement, Stress-related fatigue, Mood support.
L-Tyrosine is a non-essential amino acid that serves as a precursor for the synthesis of catecholamine neurotransmitters (dopamine, norepinephrine, and epinephrine) and thyroid hormones.
L-Tyrosine is a conditionally essential amino acid with a polar side group, one of the 20 standard amino acids used by cells to synthesize proteins. It is a small molecule modality, discovered in 1846 by German chemist Justus von Liebig in the protein casein from cheese.
At a glance
| Generic name | L-Tyrosine |
|---|---|
| Sponsor | Hadassah Medical Organization |
| Drug class | Amino acid supplement |
| Modality | Small molecule |
| Therapeutic area | Neurology, Cognitive Enhancement, Nutritional Supplement |
| Phase | FDA-approved |
Mechanism of action
L-Tyrosine is converted to L-DOPA by the enzyme tyrosine hydroxylase, which is then decarboxylated to dopamine and further metabolized to norepinephrine and epinephrine. It also serves as a substrate for thyroid hormone synthesis. Supplementation is used to support neurotransmitter production and cognitive/physical performance, particularly under stress or fatigue conditions.
Approved indications
- Cognitive performance enhancement
- Stress-related fatigue
- Mood support
- Physical performance enhancement
Common side effects
- Headache
- Nausea
- Jitteriness or anxiety
- Insomnia
Key clinical trials
- TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC (EARLY_PHASE1)
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) (PHASE3)
- Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia (PHASE2)
- A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies (PHASE1)
- Lenvatinib or Regorafenib for Advanced Hepatocellular Carcinoma After Immunotherapy (REVIVE) (PHASE2)
- The Acute Effects of Onnit Alpha Brain on Cognition and Mood States (NA)
- Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-Tyrosine CI brief — competitive landscape report
- L-Tyrosine updates RSS · CI watch RSS
- Hadassah Medical Organization portfolio CI
Frequently asked questions about L-Tyrosine
What is L-Tyrosine?
How does L-Tyrosine work?
What is L-Tyrosine used for?
Who makes L-Tyrosine?
What drug class is L-Tyrosine in?
What development phase is L-Tyrosine in?
What are the side effects of L-Tyrosine?
Related
- Drug class: All Amino acid supplement drugs
- Manufacturer: Hadassah Medical Organization — full pipeline
- Therapeutic area: All drugs in Neurology, Cognitive Enhancement, Nutritional Supplement
- Indication: Drugs for Cognitive performance enhancement
- Indication: Drugs for Stress-related fatigue
- Indication: Drugs for Mood support
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing